ID   FLO-1
AC   CVCL_2045
SY   Flo-1; FLO1; FLO
DR   BTO; BTO:0003641
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473447
DR   CCLE; FLO1_OESOPHAGUS
DR   Cell_Model_Passport; SIDM01041
DR   Cosmic; 1599339
DR   Cosmic-CLP; 1503361
DR   DepMap; ACH-001500
DR   DSMZ; ACC-698
DR   ECACC; 11012001
DR   GDSC; 1503361
DR   GEO; GSM1669793
DR   IARC_TP53; 21628
DR   PharmacoDB; FLO1_367_2019
DR   Wikidata; Q54834992
RX   DOI=10.12688/f1000research.7033.1;
RX   PubMed=9407969;
RX   PubMed=20075370;
RX   PubMed=23795680;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: ~40-50 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: TP53 p.Cys277Phe (c.830G>T) (PubMed=20075370).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.63%; Native American=0.21%; East Asian, North=0%; East Asian, South=0.68%; South Asian=0.12%; European, North=71.2%; European, South=27.15% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; DSMZ; ECACC; PubMed=20075370
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 12,13
ST   D18S51: 14,16
ST   D21S11: 30,32.2
ST   D3S1358: 15
ST   D5S818: 12,14
ST   D7S820: 8
ST   D8S1179: 13
ST   FGA: 21
ST   Penta D: 11,12
ST   Penta E: 5,17
ST   TH01: 6
ST   TPOX: 9,11
ST   vWA: 16
DI   NCIt; C4025; Esophageal adenocarcinoma
DI   ORDO; Orphanet_99976; Adenocarcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 21
//
RX   DOI=10.12688/f1000research.7033.1;
RA   Contino G., Eldridge M.D., Secrier M., Bower L., Elliott R.F., Weaver J.,
RA   Lynch A.G., Edwards P.A.W., Fitzgerald R.C.;
RT   "Whole-genome sequencing of nine esophageal adenocarcinoma cell lines.";
RL   F1000Research 5:1336-1336(2016).
//
RX   PubMed=9407969;
RA   Hughes S.J., Nambu Y., Soldes O.S., Hamstra D., Rehemtulla A.,
RA   Iannettoni M.D., Orringer M.B., Beer D.G.;
RT   "Fas/APO-1 (CD95) is not translocated to the cell membrane in
RT   esophageal adenocarcinoma.";
RL   Cancer Res. 57:5571-5578(1997).
//
RX   PubMed=20075370; DOI=10.1093/jnci/djp499;
RA   Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P.,
RA   Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K.,
RA   Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H.,
RA   Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Verification and unmasking of widely used human esophageal
RT   adenocarcinoma cell lines.";
RL   J. Natl. Cancer Inst. 102:271-274(2010).
//
RX   PubMed=23795680; DOI=10.1111/dote.12095;
RA   Boonstra J.J., Tilanus H.W., Dinjens W.N.M.;
RT   "Translational research on esophageal adenocarcinoma: from cell line
RT   to clinic.";
RL   Dis. Esophagus 28:90-96(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//